Boehringer Ingelheim Starts Phase III Registration For Hepatitis C Drug
This article was originally published in PharmAsia News
Executive Summary
Boehringer Ingelheim has started Phase 3 registration for its interferon-free triple drug polymodal therapy using protease inhibitor faldaprevir (BI 201335 NA), non-nucleoside polymerase inhibitor “BI 207127 NA”, and oral drug ribavirin for the treatment of Hepatitis C.